Bayer, Apotex settle suit over cancer drug patent
13-08-2020
Bayer begins $240m AI drug discovery project with Exscientia
10-01-2020
Sirada Wichitaphornkun / Shutterstock.com
Germany-based Bayer will pay up to $4 billion to acquire gene therapy company Asklepios BioPharmaceutical.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Bayer, Asklepios BioPharmaceutical, mergers and acquisitions, M&A, gene therapy, genetics
